Antonin de Fougerolles

Antonin (Tony) de Fougerolles is the CEO of Evox Therapeutics, leading the development of a novel therapeutic class utilizing exosomes, nature’s delivery system, to transport genetic medicines to previously inaccessible tissues. Since its founding in 2016, Evox has raised over £150m in financing and built a strong team and board. With 25 years of biotech R&D experience, Tony has contributed to the market success of mRNA, RNAi, and single domain antibodies, playing a pivotal role in companies like Moderna and Alnylam. 

Previously, as CSO of Ablynx, Tony oversaw non-clinical R&D, including the approval of caplacizumab for a rare life-threatening disease. He was also the founding CSO of Moderna, pioneering mRNA therapies and collaborating with the US government for pandemic preparedness. Tony’s career includes roles at Tolerx, Alnylam, and Biogen, where he led programs in immunology, RNAi, and therapeutic development. 

 Tony has been involved in Nasdaq IPOs, received over $80m in grants, published over 60 scientific papers, and holds over 110 issued U.S. patents. He serves on the boards of various biotech companies and earned his Ph.D. in Immunology from Harvard University. Tony continues to advance Evox’s pipeline and exosome technology platform, aiming to create a transformative drug platform and company.